Common NHS Diabetes Drug Mimics Exercise Benefits, Study Reveals
Prescription tablets already widely available on the NHS may replicate some of the crucial benefits of physical exercise, offering new hope for controlling weight and protecting cardiovascular health in individuals who are unable to stay active. Metformin, a medication taken by nearly three million people in the UK to manage type 2 diabetes, costs as little as two pence per tablet and has previously been associated with reducing cancer risks.
Groundbreaking Research from University of Miami
Now, leading scientists at the University of Miami Miller School of Medicine have discovered that this affordable drug could also elevate levels of a specific molecule released during physical exertion. This finding suggests metformin might help regulate blood sugar and enhance cardiovascular health for those whose mobility is limited by medical conditions or treatments.
'From a clinical standpoint, seeing a metabolic signal that mirrors what we associate with intense exercise was striking,' explained Dr Marijo Bilusic, a medical oncologist and the study's lead author. 'For patients whose treatments or symptoms limit physical activity, that kind of effect could be especially meaningful.'
Study Details and Molecular Insights
The research, published in the esteemed journal EMBO Molecular Medicine, meticulously examined the effects of metformin in a cohort of 29 men diagnosed with prostate cancer. Researchers conducted detailed analyses of blood samples to measure how the pill influenced N-lactoyl-phenylalanine, commonly known as Lac-Phe.
This molecule is naturally produced by the body during vigorous physical activity and has been strongly linked to appetite suppression and subsequent weight loss. The new results revealed that while metformin did not appear to directly treat prostate cancer itself, it significantly raised Lac-Phe levels in the patients—achieving this without requiring any actual exercise.
Implications for Cancer Patients and Metabolic Health
This discovery opens exciting avenues for further research into the drug's broader potential, particularly for cancer patients who frequently experience debilitating fatigue that severely limits their capacity to engage in physical workouts. 'Metabolism is involved in everything cells do,' noted David Lombard, a Sylvester researcher and professor of pathology and laboratory medicine at the Miller School.
'These findings suggest Lac-Phe may be a very informative signal for understanding how metformin affects metabolism in prostate cancer patients.' Dr Bilusic further elaborated, 'The result isn't a new cancer biomarker, but a clearer understanding of how a widely used drug may support metabolic health during prostate cancer treatment—an outcome that matters to patients and clinicians alike.'
Broader Context and Future Directions
The research team emphasised that additional work is necessary to fully explore this subject, but highlighted that their findings 'remind us cancer care isn't only about targeting tumours.' Priyamvada Rai, professor of radiation oncology at the Miller School, added, 'Supporting metabolic health can influence how patients tolerate treatment and how they feel over time, even if it doesn't directly change tumor growth.'
'This study was an opportunity to investigate molecular pathways that can be therapeutically activated for better outcomes to treatments that induce metabolic stress.' Earlier studies have already connected metformin to a reduced risk of oesophageal cancer and suggested it might also offer protective benefits against prostate cancer.
Current Uses and Growing Interest
Metformin is typically prescribed for diabetes management when dietary changes and exercise alone prove insufficient to control blood sugar levels effectively. The NHS also utilises metformin to improve fertility in women suffering from polycystic ovary syndrome, a condition characterised by irregular periods, enlarged ovaries, and excess male hormones that can lead to issues like facial hair.
In recent years, the drug has garnered increasing attention as a potential cancer-fighting agent, with various research indicating it can slow the proliferation of cancer cells. Metformin operates by lowering insulin levels, a hormone known to facilitate the multiplication of malignant cells, thereby offering a dual benefit in metabolic and oncological health.
